Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been observed to vary in its degree of symptoms. One of the most important clinical manifestations is pneumonia...
Saved in:
Main Authors: | Bogna Grygiel-Górniak, Osama Shaikh, Nikita Niranjan Kumar, Shao Heng Hsu, Włodzimierz Samborski |
---|---|
Format: | article |
Language: | EN |
Published: |
Termedia Publishing House
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/76f5289ab74b4934bde3bedbbad502ab |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?
by: Mojtaba Shafiekhani, et al.
Published: (2021) -
Tocilizumab-Induced Sweet Syndrome in a Patient With Polymyalgia Rheumatica
by: Federica Filippi, et al.
Published: (2019) -
Rheumatic fever: New ideas in diagnosis and management
by: John Lawrenson
Published: (2017) -
Features of heritable disorders of connective tissue in children with acute rheumatic fever and rheumatic heart disease
by: Oksana Boyarchuk
Published: (2020) -
Liver involvement in rheumatic diseases
by: Joanna Podgórska, et al.
Published: (2020)